Vivani Medical, Inc.

Vivani Medical, Inc. is currently overvalued and has moved from a risky to a "does not qualify" valuation grade due to poor financial health, reflected in unfavorable metrics compared to peers and significant declines in return performance relative to the S&P 500.

As of June 20, 2025, Vivani Medical, Inc. shows a neutral technical trend with mixed signals, as weekly indicators suggest mild bullish momentum while daily and monthly indicators lean bearish, indicating no strong conviction in either direction.

As of March 2022, the management team of Vivani Medical, Inc. includes Chairman Gregg Williams, Acting CEO and Director Matthew Pfeffer, Director Jonathan McGuire, and Independent Director Aaron Mendelsohn. They are responsible for the company's strategic direction and operations.

Vivani Medical, Inc. develops and markets prosthetic devices aimed at restoring vision for blind individuals, operating in the Pharmaceuticals & Biotechnology sector with a market cap of $68.13 million. The company reported a net profit loss of $6 million as of March 2025.

As of Jun 18, Vivani Medical, Inc. has a market capitalization of 68.13 million and reported net sales of 0.00 million with a net profit of -23.75 million over the last four quarters. The balance sheet shows shareholder's funds of 17.61 million and total assets of 41.56 million.